Identification and characterization of novel anti‐tau antibodies that inhibit tau‐seed mediated pathology in a P301S tauopathy mouse model Alzheimer’s Disease and tauopathies

The current hypothesis for the progression of tau pathology in Alzheimer’s disease (AD) and tauopathies (for example, Progressive supranuclear palsy (PSP)), is based on mechanisms involving seeding and propagation of pathologic tau via cell‐to‐cell transmission, including trans‐synaptic propagation, a mechanism which provides the opportunity for anti‐tau immunotherapy as a logical and promising therapy for these diseases.